Anti-H. Pylori Effect of Deep See Water

Anti-bacterial Effects of Ingesting Deep Sea Water in Subjects With H. Pylori Infection

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01933659

Enrollment

Registered

2013-09-02

Start date

2013-09-30

Completion date

2014-02-28

Last updated

2014-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori Infection

Keywords

Helicobacter pylori, deep see water

Brief summary

Deep sea water (DSW) is characterized by high purity, low temperature, high nutrients and minerals and is obtained from the water flows 200 meters under the surface of the sea. The inhibition of H. pylori growth by DSW has been demonstrated in vitro study. However, up to now, there is few randomized control study to evaluate the anti-bacterial effects of ingesting DSW in patients with H. pylori infection. The aims of this study are: 1. to evaluate the anti-bacterial effects of ingesting DSW in patients with H. pylori infection; 2. to evaluate the patient adherence and adverse effects of ingesting DSW.

Detailed description

Patients having H. pylori-positive chronic gastritis with/without small erosions or peptic ulcer scars will be recruited. Before treatment, H. pylori infection status will be examined by endoscopy with biopsy or 13C-urea breath test (13C-UBT). All patients will receive 13C-UBT before treatment, at the end of 2 week's treatment and 4 weeks after termination of treatment. A computed generated random numbers sequence will be blocked (2:1; block sizes of six) into two groups, say A and B. group A - ingesting DSW 200 cc four times a day (one hour before meal and bed time); group B - ingesting non-DSW drinking water 200 cc four times a day (one hour before meal and bed time). To keep the study in double-blind model, the picture of package for DSW and non-DSW drinking water will be the same. Prokinetics (metoclopramide 5 mg/tab 1 tid) and antacid (strocain tablet (oxethazaine 5 mg and polymigel 244 mg/tab) 1 tid) will be permitted for relieving the dyspeptic symptoms. All patients will be asked to complete a questionnaire and to record symptoms and water/drug consumption daily during the treatment period. Post-treatment, the patients will be seen at the Outpatients Clinic to investigate patient adherence and adverse of treatment.

Interventions

DRUGDSW

ingesting DSW 200 cc four times a day (one hour before meal and bed time)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients having H. pylori-positive chronic gastritis with/without small erosions or peptic ulcer scars who are aged greater than 20 years and are willing to received anti-H. pylori treatment.

Exclusion criteria

* pregnant or nursing woman * serious concomitant illness and malignant tumor of any kind * serious bleeding from gastrointestinal tract * previous gastric surgery * receiving bismuth salts, Proton pump inhibitors, or antibiotics in the previous month.

Design outcomes

Primary

Measure	Time frame	Description
to compare the efficacy of DSW and non-DSW drinking water as anti-H. pylori regimen	6 months	The eradication rates (efficacy) will be evaluated by intention-to-treat (ITT) and per-protocol (PP) analysis.

Secondary

Measure	Time frame	Description
to compare the adverse effects and patient adherence of DSW and non-DSW drinking water as anti-H. pylori regimen	6 months	The safety and patient adherence will be evaluated by the number of participant with adverse events and by counting unused medication after the treatment.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026